Back to User profile » Professor Nakao Iwata

Papers published by Professor Nakao Iwata:


Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study

Okamoto N, Watanabe K, Ngyuyen LH, Ikenouchi A, Kishi T, Iwata N, Kakeda S, Korogi Y, Yoshimura R

Neuropsychiatric Disease and Treatment 2020, 16:2569-2577

Published Date: 29 October 2020

A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder

Katsuki A, Kakeda S, Watanabe K, Igata R, Otsuka Y, Kishi T, Nguyen L, Ueda I, Iwata N, Korogi Y, Yoshimura R

Neuropsychiatric Disease and Treatment 2019, 15:2425-2432

Published Date: 23 August 2019

Rare compound heterozygous missense SPATA7 variations and risk of schizophrenia; whole-exome sequencing in a consanguineous family with affected siblings, follow-up sequencing and a case-control study

Igeta H, Watanabe Y, Morikawa R, Ikeda M, Otsuka I, Hoya S, Koizumi M, Egawa J, Hishimoto A, Iwata N, Someya T

Neuropsychiatric Disease and Treatment 2019, 15:2353-2363

Published Date: 19 August 2019

COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder

Otsuka Y, Kakeda S, Sugimoto K, Katsuki A, Nguyen LH, Igata R, Watanabe K, Ueda I, Kishi T, Iwata N, Korogi Y, Yoshimura R

Neuropsychiatric Disease and Treatment 2019, 15:1537-1545

Published Date: 6 June 2019

Genetic effects on white matter integrity in drug-naive patients with major depressive disorder: a diffusion tensor imaging study of 17 genetic loci associated with depressive symptoms

Kakeda S, Watanabe K, Katsuki A, Sugimoto K, Ueda I, Igata N, Kishi T, Iwata N, Abe O, Yoshimura R, Korogi Y

Neuropsychiatric Disease and Treatment 2019, 15:375-383

Published Date: 29 January 2019

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Kishi T, Oya K, Matsui Y, Nomura I, Sakuma K, Okuya M, Matsuda Y, Fujita K, Funahashi T, Yoshimura R, Iwata N

Neuropsychiatric Disease and Treatment 2018, 14:2519-2530

Published Date: 1 October 2018

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population

Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N

Neuropsychiatric Disease and Treatment 2017, 13:1281-1302

Published Date: 11 May 2017

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial

Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, Okochi T, Hirano S, Funahashi T, Okuda M, Tabuse H, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2017, 13:117-125

Published Date: 6 January 2017

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

Kishi T, Matsuda Y, Matsunaga S, Mukai T, Moriwaki M, Tabuse H, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2016, 12:3041-3049

Published Date: 28 November 2016

Memantine for the treatment of frontotemporal dementia: a meta-analysis

Kishi T, Matsunaga S, Iwata N

Neuropsychiatric Disease and Treatment 2015, 11:2883-2885

Published Date: 12 November 2015

Early prediction of blonanserin response in Japanese patients with schizophrenia

Kishi T, Matsuda Y, Fujita K, Iwata N

Neuropsychiatric Disease and Treatment 2014, 10:1861-1866

Published Date: 23 September 2014

COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study

Hayashi K, Yoshimura R, Kakeda S, Kishi T, Abe O, Umene-Nakano W, Katsuki A, Hori H, Ikenouchi-Sugita A, Watanabe K, Ide S, Ueda I, Moriya J, Iwata N, Korogi Y, Kubicki M, Nakamura J

Neuropsychiatric Disease and Treatment 2014, 10:1183-1190

Published Date: 25 June 2014

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder

Nagao K, Kishi T, Moriwaki M, Fujita K, Hirano S, Yamanouchi Y, Funahashi T, Iwata N

Neuropsychiatric Disease and Treatment 2013, 9:781-786

Published Date: 5 June 2013